Allogene Therapeutics (ALLO, Financial) is set to unveil updated data from its completed Phase 1 TRAVERSE trial of ALLO-316 at the upcoming American Society of Clinical Oncology Annual Meeting, scheduled for May 29-June 2, 2025, in Chicago. This trial focused on patients with advanced or metastatic renal cell carcinoma (RCC) who did not respond to prior immune checkpoint inhibitor and VEGF-targeted treatments. ALLO-316 is a unique allogeneic CAR T cell therapy targeting CD70, marking it as the sole off-the-shelf CAR T therapy showing promise in solid tumors.
The Phase 1 TRAVERSE trial previously indicated ALLO-316's manageable safety profile and promising anti-tumor activity in heavily pretreated CD70+ RCC patients. The Phase 1b expansion cohort has now completed enrollment, which examined the therapy's safety and efficacy at the second dose level following a standard lymphodepletion regimen of cyclophosphamide and fludarabine.
Simultaneously, Allogene is highlighting its ongoing pivotal Phase 2 ALPHA3 trial, which is investigating cemacabtagene ansegedleucel (cema-cel) within first-line treatment for large B-cell lymphoma (LBCL). This trial, the first of its kind, is assessing cema-cel's effectiveness in eradicating minimal residual disease (MRD) in patients after 1L chemoimmunotherapy, such as the R-CHOP regimen. Utilizing the investigational Foresight CLARITY test for MRD, this randomized study aims to enroll around 240 participants to demonstrate a significant improvement in event-free survival compared to the standard of care.
The ALPHA3 trial represents a groundbreaking approach by identifying patients at high risk for relapse post-1L treatment and attempting to boost the overall cure rates for LBCL patients.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Allogene Therapeutics Inc (ALLO, Financial) is $9.18 with a high estimate of $14.00 and a low estimate of $3.00. The average target implies an upside of 430.74% from the current price of $1.73. More detailed estimate data can be found on the Allogene Therapeutics Inc (ALLO) Forecast page.
Based on the consensus recommendation from 15 brokerage firms, Allogene Therapeutics Inc's (ALLO, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
